Intrauterine adhesions
Conditions
Interventions
Stem cell intervention group:Hormone replacement therapy + Interventional perfusion of stem cells via uterine artery
control group:Hormone replacement therapy only
Sponsors
The Sixth Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
Female
Age
20 Years to 38 Years
Inclusion criteria
Inclusion criteria: 1. Fully understand the purpose of the study and fully understand and sign the protocol; 2. The age of the subjects was 20-38 years old; 3. Body mass index (BMI) was 18-27 kg / m^2; 4. Regular menstrual cycle in at least half a year, 27-35 days; 5. Ovarian reserve was normal, AFC >= 6, serum follicle stimulating hormone (FSH) level was 1-10iu / L on day 2-4 of menstrual cycle, and other basic sex hormone indexes were within the normal range of clinical laboratory; 6. Within half a year, HIV antibody, TPPA, HBsAg and HCV Ag were negative; 7. According to Gardner's blastocyst grading standard, the number of D5 / D6 blastocysts was more than 2; 8. The previous diagnosis of severe intrauterine adhesions by hysteroscopy had been performed with electric resection. The shape of uterine cavity was basically normal within 3 months; 9. The history of frozen embryo transfer (endometrial thickness < 6 mm in HRT cycle or / and natural cycle) was cancelled due to repeated monitoring of endometrial thinness and adverse reaction by B-ultrasound.
Exclusion criteria
Exclusion criteria: 1. Patients with ovarian cyst diameter >= 20 mm, submucous myoma or intramural myoma > 30 mm, pituitary tumor and malignant tumor of various tissues and organs; 2. Patients with the abnormal uterus (endometrial polyps, intrauterine adhesions, uterine malformations, endometriosis) and adnexa (hydrosalpinx) with clinical significance; 3. Failure of repeated implantation, such as three consecutive transplants, failure of more than 6 high-quality embryos; 4. Abnormal vaginal bleeding of unknown cause; 5. Active pelvic inflammatory disease is known; 6. Malformations of reproductive organs known to be unsuitable for pregnancy; 7. Results of abnormal cervical cytology (TCT) within one year before screening; 8. Severe liver and kidney damage, heart disease, hypertension; 9. Previous or current history of thrombophlebitis or thromboembolic disease is known; 10. PLT < 100 x 10^9 / L, Hb < 100g / L; patients with hematological diseases, such as idiopathic thrombocytopenic purpura, etc; 11. Any known systemic disease with clinical significance (such as diabetes, tuberculosis, etc.); 12. Known history of recurrent abortion; 13. The chromosome karyotype of either husband or wife is abnormal; 14. Either of the husband and wife is suffering from a hereditary disease that is not suitable for childbearing as stipulated in the law on maternal and child health care; 15. Either of the husband and wife has been exposed to teratogenic radiation, poisons, and drugs; 16. Participated in clinical trials of other drugs or medical devices within 3 months before enrollment; 17. According to the investigator's judgment, there are any physical conditions / combined surgery/medication / other clinically significant abnormal laboratory tests that may affect the test results; 18. Those who are known to refuse or fail to comply with protocol requirements for any reason (including planned clinical visits and examinations).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endometrial thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate;Biochemical pregnancy rate;ongoing pregnancy rate; | — |
Countries
China
Contacts
Public ContactXiaoyan Liang
The Sixth Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed